Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Matsuda
Masayuki
M
The Third Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. matsuda@hsp.md.shinshu-u.ac.jp
Hoshi
Kenichi
K
Gono
Takahisa
T
Morita
Hiroshi
H
Ikeda
Shu-ichi
S
D000284:Administration, Oral; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008475:Median Nerve / Q000187:drug effects; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects; D009431:Neural Conduction / Q000187:drug effects; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D011506:Proteins / Q000378:metabolism; D018709:Statistics, Nonparametric; D013979:Tibial Nerve / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D011506:Proteins; D016572:Cyclosporine